Bone Quality Preservation Beyond Bone Density: A Multidimensional Approach to Skeletal Health

Abstract

Bone health has traditionally been evaluated primarily by bone mineral density (BMD); however, emerging research reveals that bone quality, encompassing microarchitecture, turnover, mineralization, and composition, critically influences fracture risk independent of BMD. This review synthesizes recent scientific evidence on bone quality, its pathophysiology, risk factors, clinical assessment, and management strategies. Special attention is given to novel diagnostic modalities, emerging therapies, and guideline recommendations, providing a comprehensive, clinically relevant perspective for healthcare professionals managing patients at risk of fragility fractures.

Introduction

Clinical interest in bone health has long focused on bone mineral density as a surrogate marker for fracture risk and osteoporosis. Yet, epidemiological data demonstrate that many patients with so-called "normal" BMD still experience fragility fractures, suggesting that bone quality plays a pivotal role in skeletal integrity. Bone quality encompasses aspects such as trabecular and cortical microarchitecture, turnover dynamics, mineral composition, and the presence of microdamage. This article reviews the multidimensional nature of bone quality, its clinical relevance, and evolving strategies for its assessment and preservation beyond traditional BMD measurements.

Epidemiology / Disease Burden

Osteoporotic fractures represent a major public health concern, with over 8.9 million fractures occurring annually worldwide. While osteoporosis is classically defined by reduced BMD, approximately half of all fragility fractures occur in individuals whose BMD values do not meet the threshold for osteoporosis. This discrepancy highlights the underappreciated burden of poor bone quality, which may go undetected in standard screening protocols. The prevalence of impaired bone quality increases with age, chronic disease, and exposure to risk factors affecting bone remodeling. As life expectancy rises globally, understanding and addressing bone quality is essential to reducing fracture incidence and associated morbidity and mortality.

Pathophysiology

Bone quality is determined by a complex interplay of factors that extend beyond mineral density. Microarchitectural integrity, both at the trabecular and cortical levels, influences mechanical strength. Trabecular thinning, loss of connectivity, and increased cortical porosity undermine bone resilience. Collagen cross-linking and mineralization contribute to bone's material properties, while bone turnover rates affect the accumulation of microdamage. Disruptions in any of these components due to aging, hormonal imbalances, medications, or metabolic diseases can compromise bone quality, rendering it more susceptible to fractures despite preserved BMD.

Risk Factors

Risk factors for impaired bone quality overlap with, but are not limited to, those influencing bone density. Aging is the leading contributor, as age-related declines in bone formation, increased resorption, and changes in collagen and mineral properties occur. Chronic glucocorticoid use, diabetes mellitus, chronic kidney disease, and inflammatory disorders accelerate changes in bone microarchitecture and turnover. Lifestyle factors such as physical inactivity, poor nutrition, excessive alcohol intake, and smoking further impair bone quality. Genetic factors and certain medications, including aromatase inhibitors and anticonvulsants, are also implicated in deteriorating bone material properties.

Clinical Features

Clinically, poor bone quality manifests primarily as increased susceptibility to low-trauma or fragility fractures, which may occur at the spine, hip, wrist, or other skeletal sites. Unlike osteomalacia, bone quality deficits often lack overt biochemical or radiographic signs until a fracture occurs. Some patients may report chronic pain, loss of height, or functional decline post-fracture. Subtle signs such as vertebral deformities on imaging or unexplained fractures in patients with normal BMD should prompt consideration of underlying bone quality deficits.

Diagnosis

Standard diagnostic tools like dual-energy X-ray absorptiometry (DXA) are limited to assessing BMD and do not capture bone quality. Advanced imaging techniques, including high-resolution peripheral quantitative computed tomography (HR-pQCT), magnetic resonance imaging (MRI), and trabecular bone score (TBS) derived from DXA, provide insights into bone microarchitecture. Bone turnover markers (e.g., CTX, P1NP) offer information on remodeling dynamics but are influenced by biological variability. In select cases, bone biopsy with histomorphometry remains the gold standard for assessing microarchitecture and turnover, though its invasiveness limits routine use. Emerging non-invasive technologies, such as reference point indentation, are under investigation for clinical application.

Treatment & Management

Management of impaired bone quality emphasizes multifactorial intervention. Calcium and vitamin D supplementation, regular weight-bearing exercise, and fall prevention are foundational strategies. Pharmacological therapies, traditionally targeting bone resorption (e.g., bisphosphonates, denosumab), also impact bone microarchitecture and turnover. Anabolic agents such as teriparatide and romosozumab stimulate bone formation and improve microstructural integrity. In secondary causes (e.g., glucocorticoid-induced osteoporosis, diabetes, chronic kidney disease), optimizing underlying disease management is crucial. Fracture liaison services and multidisciplinary care enhance secondary prevention and long-term outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advancements in therapies targeting bone quality. Sclerostin inhibitors (e.g., romosozumab) not only increase BMD but also enhance trabecular and cortical microarchitecture. Cathepsin K inhibitors, though currently limited by adverse effects, represent another class aimed at modifying bone matrix properties. Novel agents modulating collagen cross-linking and mineralization are under preclinical investigation. Research into senolytic drugs to mitigate age-related bone fragility is ongoing. Non-pharmacological advances include in vivo assessment of microdamage and material properties, potentially enabling individualized therapy selection and monitoring.

Guideline Recommendations

Current guidelines from organizations such as the International Osteoporosis Foundation and American Society for Bone and Mineral Research advocate a holistic approach to fracture risk assessment, integrating BMD with clinical risk factors and, where available, bone quality metrics. The use of FRAX and TBS is encouraged to refine risk stratification. Treatment decisions should consider both BMD and non-BMD determinants of bone strength, especially in patients with unexplained fractures or high-risk comorbidities. Ongoing guideline updates increasingly emphasize the need for research and clinical implementation of bone quality assessment in routine practice.

Conclusion

Preservation of bone quality, alongside BMD, is paramount for effective reduction of fracture risk and promotion of lifelong skeletal health. Advances in diagnostic modalities and therapeutic options are reshaping the clinical approach to bone fragility, underscoring the importance of a multidimensional evaluation and management paradigm. Future integration of bone quality assessment into standard care, guided by robust evidence and expert consensus, will enhance patient outcomes and reduce the societal burden of osteoporotic fractures.